Prevalence of specific patient populations in China

Utilizing RWD to uncover the proportion and total count of patients with genetic variations, biomarkers, and specific clinical characteristics in China.

Comparative analysis of subgroups

Revealing the clinical and molecular characteristics, treatment profiles, and outcomes (such as rwTTNT, rwOS , etc.) across different subgroups.

Exploration of novel biomarkers

For example investigating the associations and exclusivity between new targets
and known molecular biomarkers, as well as clinical and immune
microenvironment characteristics, to inform the design of future clinical trials.

Hypothesis generation and validation

Identification of key factors influencing patient prognosis or response, indicating novel therapeutic options for specific patients.

Real-world evidence

The utilization of high-quality structured real-world data enables direct translation into robust real-world evidence, thereby supporting single-arm clinical trials and the exploration of new.

~3/4 large panel tests
(400-700 genes)

~3/4 tumor tissue samp

MSI/TMB/HRD/MRD/HED
biomarkers

Full coding region coverage

CDISC/CDASH standards

Extended, structured clinical information with 200+ fields

treatment and outcome data

pathological diagnosis

HE imaging data

IHC and FISH data